These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18525183)

  • 1. [Adjuvant therapy after treatment of hepatocellular carcinoma].
    Kasai K; Kuroda H; Suzuki K
    Nihon Shokakibyo Gakkai Zasshi; 2008 Jun; 105(6):787-94. PubMed ID: 18525183
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chemoprevention of hepatocellular carcinoma by acyclic retinoid].
    Nagaki M; Shimizu M; Moriwaki H
    Nihon Shokakibyo Gakkai Zasshi; 2008 Jun; 105(6):802-7. PubMed ID: 18525185
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.
    Pinato DJ; Fessas P; Sapisochin G; Marron TU
    Hepatology; 2021 Jul; 74(1):483-490. PubMed ID: 33369758
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids.
    Shimizu M; Shirakami Y; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Moriwaki H
    Mol Nutr Food Res; 2014 Jan; 58(1):124-35. PubMed ID: 24273224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy].
    Takayama T
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():683-7. PubMed ID: 11762037
    [No Abstract]   [Full Text] [Related]  

  • 6. [Non-invasive therapy of liver neoplasm].
    Tanikawa K
    Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):1963-4. PubMed ID: 8586913
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
    Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Yamazaki M; Yamao J; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Fujimoto M; Uemura M; Fukui H
    Oncol Rep; 2011 Dec; 26(6):1547-53. PubMed ID: 21874260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative therapy options for hepatocellular carcinoma.
    Zhong JH; Ma L; Li LQ
    Scand J Gastroenterol; 2014 Jun; 49(6):649-61. PubMed ID: 24716523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic retinoids for the secondary prevention of hepatocellular carcinoma.
    Shafritz DA
    N Engl J Med; 1996 Jun; 334(24):1600-1. PubMed ID: 8628344
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of hepatocellular carcinoma recurrence: actuality and perspectives.
    Takayama T; Makuuchi M
    Hepatogastroenterology; 2002; 49(43):87-90. PubMed ID: 11941990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyprenoic acid in hepatocellular carcinoma.
    Yang CH; Cheng AL
    N Engl J Med; 1996 Nov; 335(19):1460-61; author reply 1461-2. PubMed ID: 8927081
    [No Abstract]   [Full Text] [Related]  

  • 12. [Preventive use of retinoids for occurrence of liver neoplasm].
    Muto Y
    Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):2032-7. PubMed ID: 8586927
    [No Abstract]   [Full Text] [Related]  

  • 13. Suppression of FGF signaling: a putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma.
    Wang L; Levin MS
    Gastroenterology; 2005 Jan; 128(1):228-31. PubMed ID: 15633140
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.
    Zhu GQ; Shi KQ; Yu HJ; He SY; Braddock M; Zhou MT; Chen YP; Zheng MH
    Oncotarget; 2015 Jul; 6(20):18151-61. PubMed ID: 26061709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment.
    Schlitt HJ; Schnitzbauer AA
    Liver Transpl; 2011 Nov; 17 Suppl 3():S10-2. PubMed ID: 21850696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current strategies for chemoprevention of hepatocellular carcinoma.
    Okita K; Sakaida I; Hino K
    Oncology; 2002; 62 Suppl 1():24-8. PubMed ID: 11868781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.
    Sakai H; Shirakami Y; Shimizu M
    World J Gastroenterol; 2016 Jan; 22(1):394-406. PubMed ID: 26755885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long time oral supplementation with branched-chain amino acids improves survival and decreases recurrences in patients with hepatocellular carcinoma].
    Tsuchiya K; Asahina Y; Izumi N
    Nihon Shokakibyo Gakkai Zasshi; 2008 Jun; 105(6):808-16. PubMed ID: 18525186
    [No Abstract]   [Full Text] [Related]  

  • 19. Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation.
    Wang ZY; Geng L; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):145-9. PubMed ID: 25865686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical application of vitamin K for hepatocellular carcinoma].
    Mizuta T; Ozaki I
    Clin Calcium; 2007 Nov; 17(11):1693-9. PubMed ID: 17982189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.